Having acquired French company RPG Aventis early this year, Ranbaxy is now eyeing small branded urology molecules in the United States.
The shares of Ranbaxy Laboratories fell 3.3 per cent on the bourses on Wednesday amid speculation the promoters of the country's top drugmaker were planning to dilute their stake, but the company denied any such move.
Having moved into original research, they have attracted overseas professionals looking to come back, some nudged by MNCs' narrowing research.
There is a cluster of three buildings in Gurgaon that one can easily lose in the landscape of this Delhi suburb. But once inside, you cannot miss the smell of white powder or the rustle of some 1,400 lab coats.
Ranbaxy Laboratories Ltd on Wednesday said that it has received $4 million from German pharma company Schwarz Pharma AG for further progress on the development of RBx 2258 molecule.
Take the rediff business quiz and see how much you know about India's pharmaceutical industry.
Ranbaxy Laboratories has decided to separate the two areas of research and development - drug discovery and generics/NDDS/drug development - to achieve increased focus and rigour for success.
Ranbaxy Laboratories Ltd launched an anti-retroviral product, ABACAVIR, in India. The product, bioequivalent to the innovator brand, will be marketed in India under the brand name VIROL as 300 mg tablet formulation.
Ranbaxy Laboratories has received approval from the U.S. Food and Drug Administration to manufacture and market Clarithromycin XL 1,000 mg tablets.
Pharmaceutical major Ranbaxy Laboratories on Friday said it will set up a wholly-owned subsidiary in Spain as part of its strategy to expand presence in Europe.
Its factory in Chikalthana in western India was last month hit by the British drug regulator's curb on imports from the plant over manufacturing deficiencies.
Ranbaxy Laboratories Ltd on Friday raised its equity stake to 50 per cent in Nihon Pharmaceutical Industry.
Ranbaxy Laboratories Ltd on Friday said it has received approval from the US Food and Drug Administration to manufacture and market multiple dosages of anti-diabetes drug Glimepiride tablets.
Ranbaxy Laboratories Ltd said on Thursday that it has bagged the US Food and Drug Administration's approval for manufacturing and marketing Loratadine and Pseudoephedrine Sulfate Extended-release tablets.
Ranbaxy Laboratories on Tuesday said it had received approval from US Food and Drug Administration to market a semi synthetic cephalosporin Panixine DisperDose, a generic version of Ceph International Corp, Keflex.
A random check had found that tests failed to prove the medicines were same as the patented drugs.\n
Indian drug major Ranbaxy Laboratories has got the US Food and Drug Administration nod for the manufacture and sale of Ofloxacin tablets.
Ranbaxy Laboratories on Thursday said it had received Abbreviated New Drug Application approval from the US Food and Drug Administration to manufacture and market Loratidine
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances